Maintaining access to high-quality care by optimizing ART regimens ... well-known barrier to HIV care. Investigators completed a retrospective, cross-sectional chart review of 2012-2013 clinical ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of ...

Growth in 2024 was driven by strong patient demand for our oral two-drug regimen ... look at that chart, how much of it do you think is reflecting also things like long-acting HIV.

Biotech giant Gilead Sciences, Inc. GILD is scheduled to report fourth-quarter and full-year 2024 results on Feb. 11, after ...

Gilead Sciences, Inc. GILD reported better-than-expected fourth-quarter results and provided an upbeat guidance for 2025.

Follow live updates and news coverage of the Senate confirmation hearing for RFK Jr. Stay up to date with real-time developments on key moments and outcomes for Trump’s nominee for health secretary.

Follow live updates and news coverage of the Senate confirmation hearing for RFK Jr. Stay up to date with real-time developments on key moments and outcomes for Trump’s nominee for health secretary.

Researchers identified three new all-oral drug regimens that include at least one of two new drugs for treatment of ...

With Gilead Sciences' long-acting lenacapavir unlocking a reinvigorated focus on the pre-exposure prophylaxis (PrEP) market ...